AmBisome

This page contains recent news articles, when available, and an overview of AmBisome but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Gilead Sciences Q3 Profit Rises, Tops Estimate  -  ‎Oct 20, 2009‎
Gilead said quarterly sales for Letairis, a pulmonary arterial hypertension treatment, surged 52% to $48.1 million and sales of AmBisome liposome for ... Trading Markets (press release)

SanDisk Announces Third Quarter 2009 Financial Results  -  ‎Oct 20, 2009‎
1644407 1188497 Total Antiviral products - Other International 82066 72053 239645 209389 1470231 1231533 4221278 3399597 AmBisome 77064 72884 214645 ... Reuters

GileadSciencesgibtRekord-Finanzergebnis für das dritteQuartal2009bekannt  -  ‎Oct 23, 2009‎
Truvada, Viread, Hepsera, AmBisome, Letairis, Ranexa und Cayston sind eingetragene Marken von Gilead Sciences, Inc. Atripla ist eine eingetragene Marke von ... Reuters

GileadSciencesannonce des résultats financiers record pour le troisième ...  -  ‎Oct 23, 2009‎
Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis, Ranexa et Cayston sont des marques déposées de Gilead Sciences, Inc. Atripla est une marque déposée ... Reuters

BUSINESS WIRE: Gilead Sciences gibt Rekord-Finanzergebnis für das dritte ...  -  ‎Oct 23, 2009‎
82.066 72.053 239.645 209.389 international 1.470.231 1.231.533 4.221.278 3.399.597 AmBisome 77.064 72.884 214.645 213.680 Letairis 48.073 31.656 ... Vereinigte Wirtschaftsdienste

GILD,European CHMP Adopts Positive Opinion for Aztreonam  -  ‎Jun 26, 2009‎
...an oral formulation for the treatment of chronic hepatitis B; AmBisome, amphotericin B liposome injection to treat serious invasive fungal infections; TransWorldNews (press release)

Cancer deaths and near-misses prompted drug safety review  -  ‎Mar 6, 2009‎
The drug comes in four formulations, Abelcet, Fungizone, AmBisome and Amphocil, and recommended dosage ranges from 1 to 5mg/kg. The patient safety agency Times Online

Gilead Sciences relies on CV Therapeutics, other deals to expand  -  ‎Mar 13, 2009‎
A year later, the FDA approved Gilead's AmBisome, for life-threatening fungal infections. And in 1999, the FDA also approved Gilead's Tamiflu, which Gilead San Jose Mercury News

UN: Press Conference on Maternal Girls’ Health, Neglected Tropical ...  -  ‎Feb 25, 2009‎
The most effective treatment for kala azar -– Ambisome -- was too expensive for most health ministries. For example, it was 0 per patient in Bihar, India, ISRIA (subscription)

Simple new test for kala azar  -  ‎Feb 22, 2009‎
It is also expensive, costing at least $100 in private pharmacies. The second line treatment, which is used when SSG fails, is called ambisome. East African

Gilead Roasts Fourth-Quarter Targets  -  Jan 27, 2009
The company also reported worldwide revenue of $76.4 million from Hepsera, $75.9 million from Ambisome and $36.1 million for Letairis. TheStreet.com

Gilead Sciences Announces Record Fourth Quarter and Full Year 2008 ...  -  Jan 28, 2009
Sales of AmBisome® (amphotericin B) liposome for injection for severe fungal infections increased 12 percent to $76.0 million for the fourth quarter of 2008 Lifescience-online,

Gilead Sciences annonce des résultats financiers record pour le ...  -  Jan 29, 2009
Les ventes de liposome AmBisome ® (amphotéricine B) pour injection contre les infections fongiques graves ont augmenté de 12 % pour atteindre les 76,0 Boursier.com (Communiqué de presse),

*vwd/BUSINESS WIRE: Gilead Sciences gibt Rekord-Finanzergebnisse ...  -  Jan 30, 2009
AmBisome Der Umsatz mit dem AmBisome^®-(Amphotericin B)-Liposom zur Injektion bei schwerwiegenden Pilzinfektionen erhöhte sich um 12 Prozent auf USD 76,0 ddp-direkt.de (press release),

*vwd/BUSINESS WIRE: Gilead Sciences gibt Rekord-Finanzergebnisse ...  -  Jan 30, 2009
...international 1.272.835 941.083 4.672.432 3.439.994 AmBisome 75.971 67.807 289.651 262.571 Letairis 36.176 14.754 112.855 21.020 Sonstige Produkte 2.790 Vereinigte Wirtschaftsdienste,

Journal de Pharmacie Clinique  -  Oct 30, 2008
La plupart de ces molécules (Ambisome ® , Cancidas ® , Vfend ® ) font partie des médicaments remboursés en sus du coût des groupes homogènes de séjour (GHS) Journal Pharmacie Clinique (Abonnement),

Médicos sin Fronteras refuerza la innovación en enfermedades olvidadas  -  Oct 29, 2008
MSF ha optado por un fármaco un poco más caro pero mucho más efectivo: la anfotericina B liposomal (de nombre comercial AmBisome®, producido por Gilead), Xornal,

Gilead Sciences Announces Third Quarter 2008 Financial Results  -  Oct 16, 2008
Sales of AmBisome(R) (amphotericin B) liposome for injection for severe fungal infections increased six percent to $72.9 million for the third quarter of Centre Daily Times,

Gilead Sciences annonce ses résultats financiers pour le troisième ...  -  Oct 19, 2008
Les ventes du liposome AmBisome ® (amphotéricine B) pour injection pour le traitement d'infections fongiques graves ont augmenté de six pour cent à 72,9 Fininfo (Communiqués de presse),

*vwd/BUSINESS WIRE: Gilead Sciences gibt die Finanzergebnisse des ...  -  Oct 19, 2008
AmBisome Die Produktverkäufe von AmBisome^ ®-(Amphotericin B)-Liposom zur Injektion für schwerwiegende Pilzinfektionen erreichten im dritten Quartal 2008 ddp-direkt.de,

Gilead Q3 Profit Up On Higher Sales Of AIDS Drug; Tops Street Estimate  -  Oct 16, 2008
Sales of AmBisome, an injection for severe fungal infections, advanced 6% to $72.9 million from the same quarter last year Royalty, contract and other Trading Markets (press release),

Médicos Sin Fronteras refuerza la innovación médica en ...  -  Oct 1, 2008
MSF ha optado por un fármaco un poco más caro pero mucho más efectivo: la anfotericina B liposomal (de nombre comercial AmBisome*, producido por Gilead), Europa Press - Diario Social,

“Las enfermedades olvidadas matan miles de personas cada día en ...  -  Oct 3, 2008
MSF comenzó a administrar un fármaco un poco más caro, pero mucho más efectivo: AmBisome®, producido por Gilead, cuyo tratamiento sólo dura 10 días, Guadalajara Dos Mil,

Gilead may shoot past big firms' buyout hunts  Sep 2, 2008
...it gained a sales organization and the revenue stream that came with NeXstar's drug AmBisome, a treatment for serious fungal infections.San Francisco Chronicle,

FDA Approvals: Viread and Cancidas  Aug 21, 2008
...after a 70-mg/m 2 loading dose on day 1) or 3 mg/kg IV daily of liposomal amphotericin B (AmBisome; Gilead Sciences, Inc, for Fujisawa Healthcare, Inc).Medscape (subscription)

More dead than alive - surviving kala azar  -  Jul 24, 2008
MSF in Bihar is therefore using a newer drug, liposomal amphoterycin B, marketed under the brand name Ambisome.. "This is a very good drug. Medecins Sans Frontieres,

Zoek in het archief  -  Jul 17, 2008
AmBisome For the second quarter of 2008, sales of AmBisome(R) (amphotericin B) liposome for injection for severe fungal infections were $69.8 million, Netherlands Corporate News (persbericht),

Gilead Sciences, Inc. Q2 2008 Earnings Call Transcript  -  Jul 31, 2008
Sales of AmBisome for severe fungal infections were $70 million for the second quarter of 2008, a year-over-year increase of 8%, primarily driven by a Seeking Alpha,

Earnings Preview: Gilead Sciences  -  Jul 16, 2008
Other non-HIV drugs already owned by Gilead include the hepatitis B treatment Hepsera and the fungal infection treatment AmBisome. BY THE NUMBERS: Analysts Forbes,

*vwd/BUSINESS WIRE: Gilead Sciences gibt die Finanzergebnisse des ...  -  Jul 21, 2008
AmBisome Die Produktverkäufe von AmBisome^ ®-(Amphotericin B)-Liposom zur Injektion für schwerwiegende Pilzinfektionen erreichten im zweiten Quartal 2008 ddp-direkt.de,

Gilead Sciences annonce ses résultats financiers pour le second ...  -  Jul 21, 2008
Pour le second trimestre 2008, la vente du liposome AmBisome ® (amphotéricine B) pour injection pour le traitement d’infections fongiques graves, Business Wire (press release),

Polytherics Complex technology to make drug solubility simple  -  02 Jun 2008
An unmodified liposomal formulation of amphotericin B, Gilead Sciences' AmbiSome, has been approved for treating leishmaniasis and other severe infections In-PharmaTechnologist.com,

Gilead Sciences Announces First Quarter 2008 Financial Results  -  Apr 16, 2008
Sales of AmBisome(R) (amphotericin B) liposome for injection for the first quarter of 2008 were $71.0 million, an increase of 15 percent from $61.5 million Centre Daily Times,

HIV drug sales push Gilead Sciences Q1 profit higher  -  Apr 16, 2008
...saw sales increase 16 percent to $83 million, while quarterly sales of the severe fungal infection treatment AmBisome rose 15 percent to $71 million. Bizjournals.com,

HIV Drug Sales Boost Gilead Profits  -  Apr 16, 2008
And the company reported $71 million from AmBisome for severe fungal infections, also beating the $67 million consensus target. Sales benefitted from the TheStreet.com

Gilead Sciences' HIV drug sales push 1Q profit higher  -  Apr 16, 2008
The company's hepatitis B treatment Hepsera had sales of $83 million, a 16 percent increase, while sales of the severe fungal infection treatment AmBisome Forbes,

Gilead Sciences, Inc. Q1 2008 Earnings Call Transcript  -  Apr 16, 2008
Sales of AmBisome were $71 million for the first quarter of 2008, an increase of 15% when compared to the first quarter of 2007, of which approximately 8% Seeking Alpha,

Friday's Health Winners & Losers  -  Apr 11, 2008
...as well as $79 million from Hepsera, $67 million in sales of antifungal AmBisome and $25 million from the hypertension drug Letairis. TheStreet.com

Gilead Sciences Q1 Profit Rises On HIV Drug Sales - Update [GILD]  -  Apr 16, 2008
Fungus infection treatment AmBisome reported sales increase of 15% to $71 million. Royalty, contract and other revenues, primarily from collaborations with RTT News,

AEterna Zentaris and Paladin Labs Complete Sale and Purchase of ...  -  Apr 1, 2008
Other currently available treatments are liposomal amphotericin (Ambisome®) and Paromomycin. Leishmaniasis is an infectious disease transmitted by the bite CNNMoney.com

AEZ: Sale of Miltefosine to Paladin Labs for C$9.125M  -  Mar 3, 2008
Other current available treatments are liposomal amphotericin (Ambisome(R)) and Paromomycin. KNOBIAS DISCLAIMER: All statements made in this article were Trading Markets (press release),

New nanocarriers for cancer treatment  -  Mar 2, 2008
In fact, the FDA-approved drugs Ambisome, Doxil and DaunoXome all contain liposomal formulations. Such liposomes are typically comprised of glycerol-based Nanowerk LLC,

AEterna Zentaris and Paladin Labs Announce Sale and Purchase of ...  -  Mar 3, 2008
Other current available treatments are liposomal amphotericin (Ambisome®) and Paromomycin. Leishmaniasis is an infectious disease transmitted by the bite of CNNMoney.com





Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy